3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Wilms Tumor
1
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Medulloblastoma
1
Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
6
Irinotecan
6
Vincristine
3
PM 01183
3
Nivolumab
3
X-Rays
2
Cyclophosphamide
2
temsirolimus
1
talazoparib
1
surufatinib
1
silmitasertib
1
seclidemstat
1
rubitecan
1
regorafenib
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
liposomal doxorubicin
1
irinotecan sucrosofate
1
eribulin
1
entrectinib
1
efineptakin alfa
1
dinutuximab
1
copanlisib
1
bempegaldesleukin
1
anlotinib
1
alovudine
1
abemaciclib
1
Zoledronic Acid
1
Trabectedin
1
Topotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Sarcoma, Ewing
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA